Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbinoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 8/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 5/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.62 |
| ▸ | HTR2A | P28223 | 4/20 | 0.62 |
| ▸ | SCN1A | P35498 | 4/20 | 0.62 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.62 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.62 |
| ▸ | HRH2 | P25021 | 3/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbinoxamine SCHEMBL29414093 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Rotoxamine SCHEMBL29485023 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Rotoxamine SCHEMBL141389 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL5070 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL8709373 | 0.99 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL662375 | 0.96 | CHRM2 (0.93) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL6626762 | 0.95 | CHRM2 (0.91) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL9095143 | 0.95 | CHRM2 (0.91) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL17685697 | 0.92 | CHRM2 (0.84) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL4074917 | 0.91 | CHRM2 (0.83) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806332-B2 | Compositions and methods for inhibition of SARS-CoV-2 viral infections | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220273616-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF SARS-COV-2 VIRAL INFECTIONS | TEXAS A & M UNIV SYS (US) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806332-B2 | Compositions and methods for inhibition of SARS-CoV-2 viral infections | ACE2, ACE, TMPRSS2 | HRH1 2211/4885CHRM2 4111/4885SLC6A2 2657/4885 |
| US-20220273616-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF SARS-COV-2 VIRAL INFECTIONS | ACE2, ACE, TMPRSS2 | HRH1 2211/4885CHRM2 4111/4885SLC6A2 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.